167 related articles for article (PubMed ID: 17352450)
1. A review of the therapeutic agents used in the management of polycythaemia vera.
McMullin MF
Hematol Oncol; 2007 Jun; 25(2):58-65. PubMed ID: 17352450
[TBL] [Abstract][Full Text] [Related]
2. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Boivin P
Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
[TBL] [Abstract][Full Text] [Related]
3. [Efficacious treatment of a fatal blood disease: polycythemia vera].
Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
[No Abstract] [Full Text] [Related]
4. [Polycythaemia vera--diagnosis and therapy].
Lechner K; Geissler K; Gisslinger H
Wien Klin Wochenschr; 1999 Aug; 111(15):582-9. PubMed ID: 10483672
[TBL] [Abstract][Full Text] [Related]
5. [Management of polycythaemia with pipobroman].
Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
[TBL] [Abstract][Full Text] [Related]
6. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
7. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
9. The choice of treatment in polycythaemia vera.
Najean Y; Dresch C
Drugs Exp Clin Res; 1986; 12(1-3):177-80. PubMed ID: 3525073
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory assessment and therapeutic problems in longstanding polycythaemia vera.
Rain JD
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):197-203. PubMed ID: 8036142
[TBL] [Abstract][Full Text] [Related]
11. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch H; Kiladijan JJ; Lengfelder E; Mesa R; Mc Mullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T
Br J Haematol; 2010 Mar; 148(6):961-3. PubMed ID: 19930182
[No Abstract] [Full Text] [Related]
12. Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. The French Group for the Study of Polycythemias.
Najean Y; Dresch C; Rain JD
Nouv Rev Fr Hematol (1978); 1991; 33(2):201-3. PubMed ID: 1766854
[No Abstract] [Full Text] [Related]
13. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
Najean Y
Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
[TBL] [Abstract][Full Text] [Related]
14. Observations with 5-hydroxyurea in the management of polycythaemia vera.
Nagy G; Szegedi J; Petrányi G
Ther Hung; 1972; 20(3):91-5. PubMed ID: 4652145
[No Abstract] [Full Text] [Related]
15. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
17. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
18. Impact of the consensus conference on polycythemia vera. An opportunity to change or a sign of change?
Pazart L; Carpentier F; Durocher A; Mougeot C; Najean Y; Godeau P
Int J Technol Assess Health Care; 1999; 15(3):602-7. PubMed ID: 10874386
[TBL] [Abstract][Full Text] [Related]
19. [Black discoloration of nails in polycythaemia vera].
Konrad H; Wollina U
J Dtsch Dermatol Ges; 2005 Sep; 3(9):723-5. PubMed ID: 16173981
[No Abstract] [Full Text] [Related]
20. Polycythemia vera.
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1191-210. PubMed ID: 14560782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
